FDA/industry/consumer "blue-ribbon panel" could address promotion policies -- FDA panelist.
This article was originally published in The Gray Sheet
Executive Summary
FDA/INDUSTRY/CONSUMER "BLUE-RIBBON PANEL" TO ADDRESS PROMOTIONS POLICIES was suggested by Jeffrey Brinker, MD, Johns Hopkins University, Baltimore, at a Nov. 2 hearing of the House Science/Technology Subcommittee. Brinker, who chairs FDA's Circulatory System Devices Panel, noted a "lack of communication" between FDA and industry regarding promotional policies and said that "perhaps a blue-ribbon panel" composed of industry, consumers, health care professionals and FDAers could be convened with the aim of improving the discourse.